Overview

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Status:
Completed

Trial end date:
2018-02-05

Target enrollment:

Participant gender:

Summary

The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard prompt PRP therapy. Secondary objectives include: - Comparing other visual function outcomes (including Humphrey visual field testing and study participant self-reports of visual function) in eyes receiving anti-VEGF with deferred PRP with those in eyes receiving prompt PRP. - Determining percent of eyes not requiring PRP when anti-VEGF is given in the absence of prompt PRP. - Comparing safety outcomes between treatment groups. - Comparing associated treatment and follow-up exam costs between treatment groups.

Phase:

Phase 3

Details

Lead Sponsor:

Jaeb Center for Health Research

Collaborators:

Genentech, Inc.
National Eye Institute (NEI)

Treatments:

Ranibizumab